UBS Bets Big on Biotech Turnaround, Initiates Arcellx Coverage with $100 Target
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.